Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 39

1.

Optimization of a Series of Mu Opioid Receptor (MOR) Agonists with High G Protein Signaling Bias.

Kennedy NM, Schmid CL, Ross NC, Lovell KM, Yue Z, Chen YT, Cameron MD, Bohn LM, Bannister TD.

J Med Chem. 2018 Oct 11;61(19):8895-8907. doi: 10.1021/acs.jmedchem.8b01136. Epub 2018 Sep 24.

PMID:
30199635
2.

Chemical validation and optimization of pharmacoperones targeting vasopressin type 2 receptor mutant.

Janovick JA, Spicer TP, Bannister TD, Smith E, Ganapathy V, Scampavia L.

Biochem J. 2018 Sep 25;475(18):2941-2953. doi: 10.1042/BCJ20180065.

PMID:
30068530
3.

Site-Selective γ-C(sp3 )-H and γ-C(sp2 )-H Arylation of Free Amino Esters Promoted by a Catalytic Transient Directing Group.

Lin H, Wang C, Bannister TD, Kamenecka TM.

Chemistry. 2018 Jul 5;24(38):9535-9541. doi: 10.1002/chem.201802465. Epub 2018 Jun 6.

PMID:
29775502
4.

Bias Factor and Therapeutic Window Correlate to Predict Safer Opioid Analgesics.

Schmid CL, Kennedy NM, Ross NC, Lovell KM, Yue Z, Morgenweck J, Cameron MD, Bannister TD, Bohn LM.

Cell. 2017 Nov 16;171(5):1165-1175.e13. doi: 10.1016/j.cell.2017.10.035.

5.

A Rapid Phenotypic Whole-Cell Screening Approach for the Identification of Small-Molecule Inhibitors That Counter β-Lactamase Resistance in Pseudomonas aeruginosa.

Collia D, Bannister TD, Tan H, Jin S, Langaee T, Shumate J, Scampavia L, Spicer TP.

SLAS Discov. 2018 Jan;23(1):55-64. doi: 10.1177/2472555217728489. Epub 2017 Aug 29.

6.

Pharmacoperone rescue of vasopressin 2 receptor mutants reveals unexpected constitutive activity and coupling bias.

Janovick JA, Spicer TP, Bannister TD, Scampavia L, Conn PM.

PLoS One. 2017 Aug 2;12(8):e0181830. doi: 10.1371/journal.pone.0181830. eCollection 2017.

7.

Receptor antagonism/agonism can be uncoupled from pharmacoperone activity.

Janovick JA, Spicer TP, Smith E, Bannister TD, Kenakin T, Scampavia L, Conn PM.

Mol Cell Endocrinol. 2016 Oct 15;434:176-85. doi: 10.1016/j.mce.2016.07.003. Epub 2016 Jul 4.

8.

Exploiting the co-reliance of tumours upon transport of amino acids and lactate: Gln and Tyr conjugates of MCT1 inhibitors.

Nair RN, Mishra JK, Li F, Tortosa M, Yang C, Doherty JR, Cameron M, Cleveland JL, Roush WR, Bannister TD.

Medchemcomm. 2016 May 1;7(5):900-905. Epub 2016 Feb 23.

9.

Identification of Potential Pharmacoperones Capable of Rescuing the Functionality of Misfolded Vasopressin 2 Receptor Involved in Nephrogenic Diabetes Insipidus.

Smith E, Janovick JA, Bannister TD, Shumate J, Scampavia L, Conn PM, Spicer TP.

J Biomol Screen. 2016 Sep;21(8):824-31. doi: 10.1177/1087057116653925. Epub 2016 Jun 8.

10.

Preparation of tetrasubstituted pyrimido[4,5-d]pyrimidine diones.

Wang H, Wang C, Bannister TD.

Tetrahedron Lett. 2015 Apr 8;56(15):1949-4952.

11.

Synthesis and Cytoxicity of Sempervirine and Analogues.

Pan X, Yang C, Cleveland JL, Bannister TD.

J Org Chem. 2016 Mar 4;81(5):2194-200. doi: 10.1021/acs.joc.6b00022. Epub 2016 Feb 10.

12.

ML264, A Novel Small-Molecule Compound That Potently Inhibits Growth of Colorectal Cancer.

Ruiz de Sabando A, Wang C, He Y, García-Barros M, Kim J, Shroyer KR, Bannister TD, Yang VW, Bialkowska AB.

Mol Cancer Ther. 2016 Jan;15(1):72-83. doi: 10.1158/1535-7163.MCT-15-0600. Epub 2015 Nov 30.

13.

Selective Targeting of Extracellular Insulin-Degrading Enzyme by Quasi-Irreversible Thiol-Modifying Inhibitors.

Abdul-Hay SO, Bannister TD, Wang H, Cameron MD, Caulfield TR, Masson A, Bertrand J, Howard EA, McGuire MP, Crisafulli U, Rosenberry TR, Topper CL, Thompson CR, Schürer SC, Madoux F, Hodder P, Leissring MA.

ACS Chem Biol. 2015 Dec 18;10(12):2716-24. doi: 10.1021/acschembio.5b00334. Epub 2015 Sep 30.

PMID:
26398879
14.
15.

Identification of small molecules that disrupt signaling between ABL and its positive regulator RIN1.

Ting PY, Damoiseaux R, Titz B, Bradley KA, Graeber TG, Fernández-Vega V, Bannister TD, Chase P, Nair R, Scampavia L, Hodder P, Spicer TP, Colicelli J.

PLoS One. 2015 Mar 26;10(3):e0121833. doi: 10.1371/journal.pone.0121833. eCollection 2015.

16.
17.

Synthesis and structure-activity relationships of pteridine dione and trione monocarboxylate transporter 1 inhibitors.

Wang H, Yang C, Doherty JR, Roush WR, Cleveland JL, Bannister TD.

J Med Chem. 2014 Sep 11;57(17):7317-24. doi: 10.1021/jm500640x. Epub 2014 Aug 22.

18.

ML345, A Small-Molecule Inhibitor of the Insulin-Degrading Enzyme (IDE).

Bannister TD, Wang H, Abdul-Hay SO, Masson A, Madoux F, Ferguson J, Mercer BA, Schurer S, Zuhl A, Cravatt BF, Leissring MA, Hodder P.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2012 Dec 17 [updated 2014 May 13].

19.

Grubbs cross-metathesis pathway for a scalable synthesis of γ-keto-α,β-unsaturated esters.

Nair RN, Bannister TD.

J Org Chem. 2014 Feb 7;79(3):1467-72. doi: 10.1021/jo4023606. Epub 2014 Jan 21.

20.

Blocking lactate export by inhibiting the Myc target MCT1 Disables glycolysis and glutathione synthesis.

Doherty JR, Yang C, Scott KE, Cameron MD, Fallahi M, Li W, Hall MA, Amelio AL, Mishra JK, Li F, Tortosa M, Genau HM, Rounbehler RJ, Lu Y, Dang CV, Kumar KG, Butler AA, Bannister TD, Hooper AT, Unsal-Kacmaz K, Roush WR, Cleveland JL.

Cancer Res. 2014 Feb 1;74(3):908-20. doi: 10.1158/0008-5472.CAN-13-2034. Epub 2013 Nov 27.

Supplemental Content

Loading ...
Support Center